Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients.
Stögbauer F, Geß B, Brambs C, Lautizi M, Kacprowski T, Ourailidis I, Bronger H, Kiechle M, Noske A, Keller G, Jesinghaus M, Poremba C, Weichert W, Boxberg M. Stögbauer F, et al. Among authors: bronger h. Cancers (Basel). 2023 Jul 28;15(15):3832. doi: 10.3390/cancers15153832. Cancers (Basel). 2023. PMID: 37568650 Free PMC article.
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B, Stögbauer F, Steiger K, Jesinghaus M, Kuhn PH, Brambs C, Engel J, Bronger H, Schmidt GP, Haller B, Weichert W, Keller G, Noske A, Pfarr N, Boxberg M. Willvonseder B, et al. Among authors: bronger h. Cancer Immunol Immunother. 2021 Jun;70(6):1679-1689. doi: 10.1007/s00262-020-02813-3. Epub 2020 Dec 19. Cancer Immunol Immunother. 2021. PMID: 33340331 Free PMC article.
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo.
Dreyer TF, Kuhn S, Stange C, Heithorst N, Schilling D, Jelsma J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H. Dreyer TF, et al. Among authors: bronger h. Cancer Immunol Res. 2021 Jul;9(7):779-789. doi: 10.1158/2326-6066.CIR-20-0327. Epub 2021 Apr 27. Cancer Immunol Res. 2021. PMID: 33906866
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
Seitz S, Dreyer TF, Stange C, Steiger K, Bräuer R, Scheutz L, Multhoff G, Weichert W, Kiechle M, Magdolen V, Bronger H. Seitz S, et al. Among authors: bronger h. Br J Cancer. 2022 Jun;126(10):1470-1480. doi: 10.1038/s41416-022-01763-0. Epub 2022 Mar 21. Br J Cancer. 2022. PMID: 35314795 Free PMC article.
Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients.
Avril S, Dincer Y, Malinowsky K, Wolff C, Gündisch S, Hapfelmeier A, Boxberg M, Bronger H, Becker KF, Schmalfeldt B. Avril S, et al. Among authors: bronger h. Oncotarget. 2017 Jun 8;8(58):97851-97861. doi: 10.18632/oncotarget.18415. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228656 Free PMC article.
45 results